SCHEMBL6783687

SCHEMBL6783687

CC(C)(C)OC(=O)NC(CC(=O)OCOC(=O)C(C)(C)C)c1cc(Cl)cc(Cl)c1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CACNA1B Q00975 1/20 0.37
ALDH1A1 P00352 2/20 0.35
MAPT P10636 2/20 0.35
GAA P10253 2/20 0.35
KDM4E B2RXH2 1/20 0.35
PKM P14618 1/20 0.35
HPGD P15428 1/20 0.35
ALOX12 P18054 1/20 0.35
CYP2D6 P10635 1/20 0.34
CTSL P07711 1/20 0.34
GRN P28799 2/20 0.34
SORT1 Q99523 2/20 0.34
TRPA1 O75762 1/20 0.34
APP P05067 1/20 0.34
PPARG P37231 1/20 0.33
PPARA Q07869 1/20 0.33
AAK1 Q2M2I8 1/20 0.33
KLK5 Q9Y337 1/20 0.33
CTSS P25774 1/20 0.33
CTSK P43235 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6778313 0.81 CYP26A1 (0.42) CTSLGRNSORT1TRPA1PPARG
SCHEMBL31089139 0.76 CACNA1B (0.39) CACNA1BALDH1A1MAPTGAAKDM4E
SCHEMBL16918557 0.76 MAPT (0.38) CACNA1BALDH1A1MAPTGAAKDM4E
SCHEMBL16918482 0.76 MAPT (0.38) CACNA1BALDH1A1MAPTGAAKDM4E
SCHEMBL16918558 0.76 MAPT (0.38) CACNA1BALDH1A1MAPTGAAKDM4E
Hydrochloric Acid SCHEMBL6773877 0.75 LMNA (0.34) ALDH1A1GAACYP2D6GRNSORT1
SCHEMBL24037104 0.74 GPR139 (0.37) CACNA1BALDH1A1MAPTGAAKDM4E
SCHEMBL392792 0.73 CACNA1B (0.45) CACNA1BALDH1A1MAPTGAAPKM
SCHEMBL390389 0.73 CACNA1B (0.45) CACNA1BALDH1A1MAPTGAAPKM
SCHEMBL390390 0.73 CACNA1B (0.45) CACNA1BALDH1A1MAPTGAAPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6831199-B1 In order to avoid bleeding side-effects when treating the conditions associated with integrin alpha v beta 3, it is beneficial to have compounds which are selective antagonists for alpha v beta 3 versus alpha IIb beta 3 G. D. SEARLE & CO. 2004-12-14 US disclosed
EP-0850221-B1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS SEARLE & CO (US) 2001-07-18 EP disclosed
US-6028223-A AN INTEGRIN ANTAGONISTS TREATING BONE DISORDER, PERIODONTAL DISEASE, OSTEOPOROSIS, HUMORAL HYPERCALCEMIA OF MALIGNANCY, PAGET'S DISEASE, TUMOR ANGIOGENESIS, DIABETIC RETINOPATHY, ARTHRITIS, SMOOTH MUSCLE CELL MIGRATION AND RESTENOSIS G. D. SEARLE & CO. (US) 2000-02-22 US disclosed